The Medical Letter on Drugs and Therapeutics
Generic Drugs Revisited
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The equivalence of generic drugs to their brand-name precursors continues to be controversial. The last Medical Letter review of this subject (2002) concluded that well-documented therapeutic inequivalence between brand-name and FDA-approved generic drugs had not been reported.1 Is that still true? New data have become available for some drugs.

CARDIOVASCULAR DRUGS — A systematic review and meta-analysis of 47 studies comparing generic and brand-name drugs used to treat cardiovascular disease, particularly beta-blockers, calcium channel blockers, diuretics and warfarin, found no evidence that brand-name drugs were superior to their generic counterparts. In randomized controlled trials, clinical outcomes with brand-name drugs were not any better than with generic drugs in 7 of 7 trials of beta-blockers, 10 of 11 trials of diuretics, 5 of 7 trials of calcium channel blockers and 5 of 5 trials of ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Generic Drugs Revisited
Article code: 1323a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian